| Year |
Citation |
Score |
| 2018 |
Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck P, Montrasio F, Nitsch RM, Hirst WD, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of Disease. PMID 30381260 DOI: 10.1016/j.nbd.2018.10.016 |
0.321 |
|
| 2017 |
Chung CY, Khurana V, Yi S, Sahni N, Loh KH, Auluck PK, Baru V, Udeshi ND, Freyzon Y, Carr SA, Hill DE, Vidal M, Ting AY, Lindquist S. In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons. Cell Systems. PMID 28131823 DOI: 10.1016/J.Cels.2017.01.002 |
0.689 |
|
| 2017 |
Khurana V, Peng J, Chung CY, Auluck PK, Fanning S, Tardiff DF, Bartels T, Koeva M, Eichhorn SW, Benyamini H, Lou Y, Nutter-Upham A, Baru V, Freyzon Y, Tuncbag N, et al. Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways. Cell Systems. PMID 28131822 DOI: 10.1016/J.Cels.2016.12.011 |
0.676 |
|
| 2014 |
Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X, Ben-Johny M, Soste M, Picotti P, Kim H, Caldwell KA, Caldwell GA, Sulzer D, Yue DT, et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proceedings of the National Academy of Sciences of the United States of America. 111: E3544-52. PMID 25122673 DOI: 10.1073/Pnas.1413201111 |
0.567 |
|
| 2013 |
Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (New York, N.Y.). 342: 983-7. PMID 24158904 DOI: 10.1126/Science.1245296 |
0.704 |
|
| 2011 |
di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Research. 71: 19-28. PMID 21199795 DOI: 10.1158/0008-5472.Can-10-2602 |
0.657 |
|
| 2010 |
Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annual Review of Cell and Developmental Biology. 26: 211-33. PMID 20500090 DOI: 10.1146/Annurev.Cellbio.042308.113313 |
0.596 |
|
| 2010 |
Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Disease Models & Mechanisms. 3: 194-208. PMID 20038714 DOI: 10.1242/Dmm.004267 |
0.731 |
|
| 2009 |
Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, Chesselet MF, Lindquist S. Context dependent neuroprotective properties of prion protein (PrP). Prion. 3: 240-9. PMID 19901559 DOI: 10.4161/Pri.3.4.10135 |
0.7 |
|
| 2009 |
Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, Lindquist S, Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nature Genetics. 41: 316-23. PMID 19234470 DOI: 10.1038/Ng.337 |
0.682 |
|
| 2009 |
Scheithauer BW, Swearingen B, Whyte ET, Auluck PK, Stemmer-Rachamimov AO. Ependymoma of the sella turcica: a variant of pituicytoma. Human Pathology. 40: 435-40. PMID 18992914 DOI: 10.1016/J.Humpath.2008.08.013 |
0.48 |
|
| 2008 |
di Tomaso E, Frosch MP, Auluck PK, Cahill D, Duda DG, Plotkin SR, Loeffler JS, Sorensen AG, Batchelor TT, Jain RK. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment Journal of Clinical Oncology. 26: 2009-2009. DOI: 10.1200/Jco.2008.26.15_Suppl.2009 |
0.5 |
|
| 2005 |
Auluck PK, Meulener MC, Bonini NM. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. The Journal of Biological Chemistry. 280: 2873-8. PMID 15556931 DOI: 10.1074/jbc.M412106200 |
0.7 |
|
| 2002 |
Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nature Medicine. 8: 1185-6. PMID 12411925 DOI: 10.1038/nm1102-1185 |
0.559 |
|
| 2002 |
Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (New York, N.Y.). 295: 865-8. PMID 11823645 DOI: 10.1126/Science.1067389 |
0.668 |
|
| Show low-probability matches. |
